2024 Enterprise Awards Tribute Journal - PACT

ThankYouSponsors

TitleSponsor: JudgingPartner:

AwardSponsors:

EventSponsors:

Welcometothe31stAnnualEnterpriseAwards!

Welcome to theAnnual Enterprise Awards, a celebration of Philadelphia’s entrepreneurialspiritandinnovation . Tonight, we gather to honorthe remarkableachievements of ourcity’s visionaries and trailblazers .

Despite challenges, ourlife sciencessectorcontinues to shine, driving forward with groundbreaking discoveries andtransformative innovations . Philadelphia’sresilience, particularly in pre-seed andseedstages, is evident with $2 .4B across 403 deals(as shownin our 2023 Philadelphia Venture ReportwithPitchbook), showcasing our city as a hub forearly-stageinvestment andinnovation . The surprisingknock-on effectsof valuationtrends further solidify ourposition as adynamicand competitive market . Across diverse sectors, ourmetro area’sresiliencespeaks volumesaboutour strength and adaptability .

Tonight, aswe celebrate our finalistsand winners, letus alsocelebrate our collective spiritof collaboration, determination, and positivechange

I extend my heartfelt gratitude toour Sponsorsfor their unwavering support .Thank youall for joining us in celebrating Philadelphia’sleading companies and becoming ambassadorsof theirremarkable journeys

Here’s to another yearofextraordinaryachievementsandboundless possibilities .

Dean E . Miller,PACT P President & CEO

2024 EnterpriseAwards Ceremony

AWARDS

MAY2 A 1, 2024 5:30PM

HOSTEDBY

Dean Miller

President &CEO,PACT P

and

Stephanie Humphrey

Technology & Lifestyle Contributer, Merit StreetMedia & PACT Board Member

AWARDORDER

Life Sciences&Healthcare Startup

Technology Startup

Life Sciences & HealthcareInvestmentDeal

Technology Investment Deal

Life Sciences & Healthcare Emerging

TechnologyEmerging

Life Sciences & Healthcare CEO

Technology CEO

Healthcare Innovator

HarmonyBiosciencesisarapidlygrowingCNS-focusedcompanythatis dedicatedtobringinginnovativemedicinestopatientslivingwithunmetmedical needs.HeadquarteredinPlymouthMeeting,Pennsylvania,ourteamofexperts fromawidevarietyofdisciplines,backgroundsandexperiencesisdrivenbyour sharedconvictionthatinnovativesciencetranslatesintotherapeuticpossibilities forpatients,whoaretheheartofeverythingwedo.

HarmonyBiosciences.com

LifeSciences&HealthcareStartup

CRITERIA:

• Company musthave been founded,launchedmeaningful operations, or pivotedto current strategic focusat some pointin the period between January 1, 2020,andDecember 31, 2023 .

• Company musthaveitsHQ orsignificantoperations inthe region andasignificant portion of itsleadership,employees, and consultants must be basedin theregion .

KEYCONSIDERATIONS:

•Product innovation including unmet market need andhow thatis uniquely addressed by your product/service .

• Management team andits record of achieving success

• Demonstrationof success (e .g .,significant milestones, raisingcapital, revenue, etc .) .

• R&Dinvestment strategy

• Strategies toovercome challenges in financing,development, or commercialization .

TechnologyStartup

Atechnology companymust eitherprovide proprietary technology or intellectual property or services thatleverage r proprietary technology or IP. P

CRITERIA:

• Company should have been founded,launched meaningful operations, or pivotedto current strategic focus at some pointin the period between January 1, 2020, andDecember31, 2023 .

• Company musthaveitsHQ or significant operations inthe region and asignificant portion of itsleadership,employees, and consultants must be basedin theregion .

KEYCONSIDERATIONS:

• Product or service innovationincluding market need or assessment .

• Potential forsignificant growth

• Management teamandits record of achievingsuccess .

•A demonstration of successsuch as significant milestones, raising capital, and revenue

Ourfinancialsolutionsforearly-stagestartups,venture-backed andhigh-growthcompaniescangrowwithyouateverystage.

©2024JPMorganChase&Co.Allrightsreserved.JPMorganChaseBank,N.A.MemberFDIC.

LifeSciences&HealthcareInvestmentDeal

CRITERIA:

• Deal musthave beenfully executed betweenNovember1, 2022, andOctober31, 2023 .

• CompanymusthaveitsHQ orsignificant operations inthe region andasignificant portion of itsleadership,employees and consultants must bebasedin the region .

• Eventsthat qualify for this category include: IPO, Capital Raise, Buy-sideor Sell-sideof a Merger &Acquisition Transaction .

KEYCONSIDERATIONS:

• Realized returnsfor theinvestors and management

• EBITDAmarginand revenue growth .

• Strategic considerations of thedeal (e g commercialstrategy,innovation,and contribution to market development .

• Companyperformance prior totransaction

•How thesaleorpurchaseimpacted the broader industry(s) of the buyer and/or seller .

TechnologyInvestmentDeal

CRITERIA:

• Deal musthave been fully executed betweenNovember1, 2022, and October 31, 2023 .

• Company musthaveitsHQ or significant operations inthe region and asignificant portion of its leadership,employees and consultants must be based in the region .

• Eventsthat qualify for thiscategory include: IPO, Capital Raise, Buy-side or Sell-sideof a Merger & Acquisition Transaction .

KEYCONSIDERATIONS:

• Realized returnsfor theinvestors and management

• EBITDA margin and revenue growth .

• Strategic considerations of the deal (e g commercial strategy,innovation,and contribution to market development .

• Companyperformance prior totransaction

• How thesaleorpurchaseimpacted thebroader industry(s) of thebuyer and/or seller .

AlwaysThinkingForward

LifeSciences&HealthcareEmerging

CRITERIA:

• Company musthave been in operation beginning on January 1, 2020 . The Company shouldhave no more than 8 yearsofoperating resultssince itsfounding .

• Must havesales, grants,orlicensing fees .

• CompanymusthaveitsHQ orsignificantoperations inthe region andasignificant portion of its leadership, employees, andconsultantsmust bebasedin the region .

KEYCONSIDERATIONS:

•Product or servi r ce,including proprietary applicationsorother competitiveadvantage .

• Theimpact on theclinicalproblem this product or innovationis trying tosolve (e .g . saving a hospital money on aprocedure, making aclinician more productive, etc .) .

• Companymilestones including strategicdecisions madebythe management team that ledtogrowth in revenues and/orearnings, corporatecollaborations, or licensedeals (e .g . ability to raise capital, strategy toachieve break even,ability to realize high gross margins, etc )

TechnologyEmerging

A technology companymusteitherprovide proprietary technology or intellectual property orservices v thatleverage r proprietary technology or IP. P

CRITERIA:

• Company musthave been in operation beforeJanuary 1, 2020 . Revenues must be lessthan $50M . If revenuesare projected toexceed $50M in 2023, pleasecompletetheTechnology Company application .

• Company musthaveitsHQ or significant operations inthe region and asignificant portion of its leadership, employees, and consultantsmust bebasedin the region .

KEYCONSIDERATIONS:

• Product or servi r ce innovation, including proprietary technology or other advantage

• Companymilestones including strategic decisions made bymanagement that led to growth inrevenues and/or earnings

• Strength ofmanagementteam includingability to raisecapital .

• Demonstration of asustainableand scalable business model

Weareproudtosponsorthe

LIFESCIENCES & HEALTHCARE CEO AWARD

andthe 2024PACTEnterpriseAwards

AtMorganLewis,weunderstandtheuniquechallengesfacedby leadersinthelifesciencesandhealthcareindustriesandwould liketocongratulateallofthenomineesandawardwinnersfor theircontinueddedicationtoadvancinginnovationsinhealthcare andlifesciencesintheregion.

Our EmergingCompanies&VentureCapitalPractice(ECVC) offerspersonalizedandeffectivelong-termrepresentation tailoredtoyourgrowthneedsfromstartuptomaturity.

Our Startup&Accelerate resourcecenterprovidesanalysisand thinkingrelatedtoyourstartupandhowyoucanquicklybegin movingyourventureforward.

LifeSciences&HealthcareCEO

CRITERIA:

•Individual’sbackgroundandthe company’s successto date .

• Company mustbe basedin theregionand theircompanymusthavetheirHQ or significantoperations in the regionandasignificant portionof its leadership,employees, andconsultants must be basedin theregion .

• CEO mustbe inher/his positionfor at least2 years .

KEYCONSIDERATIONS:

• CEO’s managementaccomplishments and philosophy, including the communicationof avision and goals as achievedby the company .

• Leadershipandimpactin industrya r nd/ormarket .

• Ability to attract andretain talented resources .

• Companymilestonesincludingfinancial accomplishmentsand astrategyfor continued company success .

• Community/industryinvolvement .

• Extraconsiderationis given to leaders whohave contributedmore broadly to thestrengthening and promotionofthe life sciences/healthcare industry in theregion .

• Ability toattract and retain talented resources .

TechnologyCEO

Atechnology companymust eitherprovide proprietary technology or intellectual property or services thatleverage r proprietary technology or IP. P

CRITERIA:

• Individual’sbackground andthe company’s success to date .

• CEO mustbe basedinthe region and their company must have itsHQ or significant operations in theregion andasignificant portionof its leadership,employees, andconsultants must be based in the region .

• CEO must beinher/his positionfor at least 2years .

KEYCONSIDERATIONS:

• CEO’s managementaccomplishments andphilosophy, includingthe communicationof avision and goalsasachieved bythecompany .

• Leadershipand impact in industrya r nd/ormarket .

• Abilityto attract and retain talented resources .

• Companymilestones including financial accomplishments and a strategy forcontinued company success .

• Community/industryinvolvement

• Extraconsideration is given toleaders who havecontributed more broadly to the strengthening and promotionof the technologyindustry in the region

HealthcareInnovator

CRITERIA:

• The nominee canbea company, researcher,orinvestor providing aninnovativesolutionthathas the potentialtomake a large andpositiveimpacton cost, quality, and/oraccessin health care .

• Company musthaveitsHQ orsignificantoperations inthe region andasignificant portion of its leadership, employees, andconsultantsmust bebasedin the region .

KEYCONSIDERATIONS:

• The nomineemustdemonstratecreativity and passion to re-thinking healthcare in theregion and to drivingexceptionalhealth outcomesor dramatically lowingcosts .

• Thenominee should have ademonstratedbusinessmodel foritssolutionanddemonstrate the abilityto generaterapid growth oradoption .

• The nominee should beable to demonstratereturn on investmentorclinicalimpactof itssolution

• The nominee canbe inany sector (technology, lifesciences,investment, health care delivery, etc .), butmust be servingthe healthcare industryin GreaterPhiladelphia

LeadJudge

RickRiegel Chairman, ActiGraph andDeerfield

Andrew Cherry Partner, r KPMG

TECHNOLOGYJUDGES

SuchitBachalli

ChiefExe E cutive Officer Unilog

Mike Bachman

GlobalArchitect &Pri P ncipal Technologist Boomi

SeanDowling Partner Osage Partners

Alex King Co-Managing Partner PlainSight Capital

Rick Nucci

ChiefExe E cutive Officer Guru TechnologyJudgingPanelOversight

Bharat Santhanam Principal NewSpring Capital

Sneha Shah EVPNewBusiness Ventures SEI

KweliWashington ChiefPeople Officer Piano Software

MarkWeinstein Chairman of Board of Directors Strategikon Pharma

Tom Koncsics Partner, r KPMG

LIFESCIENCES&HEALTHCAREJUDGES

TomAnderson Former CEO SwanBio

Carol Burns Co-Found F er,P r President & CEO CagentVascular

Mike DeFeo Jr. Vice President, Life Sciences Commercial Banking

J .P . Morgan Chase

Gerianne (Gerie) DiPiano Chairman &CEO FemmePharma

TiaraDurham Director of New Ventures r University City Science Center

Jennifer Strong Partner, r KPMG

Audrey Greenberg Co-Founder F &Chief Business Officer Center for Breakthrough Medicines, now SK pharmteco

Eric Heil Managing Partner Medical Excellence Capital

Jackie Hollenbach Vice President,Research and Development Teleflex

Joan Lau Chief Executive x Officer Spirovant Sciences

MatthewReber Partner 1315 Capital

Blank Romeisproud to support PACT andall of its membersintheir continueddedicationand commitmenttoinnovation, growth, andthe community.

CodeBiotherapeutics

CodeBio’snon-viralapproach to geneticmedicinedelivery providesthe potential to bea next generation productoffering following the AAVA based genetherapy andsiRNA-based therapeuticsthatare being marketedand/or approvedtoday . As aDNA-based, non-viral vector,a3DNA-based genetic medicine maypotentially bedosedevenif someone has already received another gene therapy .The breadthofutility of the 3DNA platform meansit canpotentially beused totreatboth rare and prevalentgeneticdiseases . CodeBio has assembled a diverse team and has generateddatato advance it’s initial pipeline program in Duchenne Muscular Dystrophy(DMD) into preclinical development

iECURE

iECUREis aclinical-stage biotechcompany focused on developingtherapies that utilizemutation-agnostic in vivo geneediting for the treatment of liver disorders with significant unmet need . Theirapproach hasthepotential to replaceand restorethefunctionof a dysfunctional gene, regardless of mutation,by knocking-ina healthycopy of that gene to offerdurable gene expressionand long-term, potentially curative, therapeutic benefit iECURE’s lead candidateECUR-506is aninvestigational gene editingtherapy designed to address the underlying genetic cause of Ornithine Transcarbamylase (OTC) deficiency . ECUR-506 represents thefirstin vivo gene insertion program authorized forclinical investigation inmaleinfants in the U S

Trialbee

Trialbee has emerged as agloballeaderin utilizing technology to help biopharma companies solvethe number onechallengein clinical development– enrolling patients into their clinicaltrials . In 2020 thecompany established new leadership and refocused thecompany’s strategy on technology . Inthe pastthree yearsthebusiness achieved a revenue CAGR of 100% whiletripling the employee base .Today Trialbee’ global platform enrolls patientsintoclinical trials across dozens of countries for 8of the top 10 globalpharmaceutical companies .

Sponsor:

Mineralys Therapeutics, Inc. wasfounded in 2020withthe licensingof MLS-101 (lorundrostat) from Mitsubishi Tanabe Pharma Company Mineralyshas raised approximately $500M grossproceeds through SeriaA ,Series B,IPO andPIPE financings to furtherthe development of lorundrostat.Lorundrostatisa selective aldosterone synthase inhibitor that is beingdeveloped to target masked hyperaldosteronism in cardiorenalmetabolic diseases.In a phase 2,dose-range findings, proof- of-concept study, lorundrostat delivereddouble- digit placeboadjusted reduction in systolic blood pressure while demonstrating a safe andwell-tolerated profile Lorundrostat is currently in three pivotal studiesfor hypertension and one PoC for hypertension and CKD

Thankyouforleadingour region’ssignificantcontributions totechnology,lifesciences, andhealthcare.

Adaptimmuneisworkingtoredefinethetreatmentofsolidtumorcancerswith personalizedmedicines.Weusecelltherapiestotackledifficult-to-treatsolid tumorcancersbyengineeringaperson’sownT-cellto fighttheircancer.We’rea fullyintegratedcelltherapycompanywithfourlocationsinbiotechnologyhubs intheU.S.andU.K.,includingU.S.headquartersinPhiladelphia.

Armingcells.Againstcancer.Forgood.

www.adaptimmune.com

Carenostics

Carenostics, a pioneering healthcare AIstartup, revolutionizes chronic disease management by leveraging electronic health records toidentify undiagnosedandundertreated patients .Specifically, Carenostics partners withhealth systemsto proactively identify high-riskchronic disease patients andenable earlier clinical interventionto avoid preventable complications, hospitalizations,anddeaths .Carenostics’award-winning PREDICT platform is adaptable across diseases to significantlyincreasediagnoses,identifying 3X more Chronic KidneyDisease patients and 20X Severe Uncontrolled Asthmapatientscompared tostandard practices . By integratingthese insightsbackinto clinical workflowsand drivingindustry-leadingclinical adoption rates,Carenostics drives increased preventativeinterventionto radicallyimprovepatient outcomes

MuralHealth

MuralHealthwas foundedin2022 tomakeclinical trial participationeasier . MuralLink, afirst-of-its-kind participantmanagement platform, was designed by co-founder andCEO, Sam Whitaker, inventorof ClinCard,theindustry’s first participant payment technology product in 2008 MuralLink represents adisruptionof thisoriginal platform, expanding itsfunctionality to meet theneeds of modern-day participants Mural Link’s initialfeaturesinclude next-gen paymentprocessing, transportation,two-way messaging,and participant feedback Mural Linkhelps participants overcomeenrollment and retentionbarriers,improves site operations, anddeliversgreater strategic value to sponsors .In 2023, MuralHealth raised $8M in seedfunding .

RedVector

Red Vector offers aninnovativesoftware platform,FULCRUM®, to empower organizations in monitoring and managing organizationalrisk . Red Vector equipsenterprises with actionable visibility into insider threat, whichis criticalto uncovering previouslyunidentified risks and prompting early detection and resolution .

Sponsor:

Bank of America would like to congratulate allofthe 2024 Enterprise Awardnominees and winners .We applaud youfor being recognized with one of the region’s most prestigious businesshonors for technology and lifesciences companies, leaders, andentrepreneurs. Thank you for yourcontinueddedication

bankofamerica.com/about ©2023

HarmonyBiosciences

Harmonyisa commercial-stage pharmaceuticalcompany dedicatedto developing andcommercializing innovative therapies for people withrare neurologicaldisorders . As part ofits growthstrategy,Harmony acquired Zynerba,whose asset isa‘portfolioina product’ and the first-and-only pharmaceutically manufactured synthetic,non-euphoric cannabidiol formulatedasa patent-protected permeation-enhanced gelfordelivery throughskin Harmony paid approximately $60Min cashupon theclosingofthetransaction and received approximately $26Min cash and $45M in deferred taxassets fromthe acquisition . Harmony acquired 2late-stage programs that have an international intellectual propertyportfolioincluding seven U S patents and one EU patentrelated tomethodsof treatingFragile Xsyndrome, 22q11 .2 deletion syndromeand autism spectrumdisorder

Mineralys

Mineralys Therapeutics was founded in 2020 with the licensingof MLS-101 (lorundrostat) fromMitsubishi Tanabe Pharma Mineralys has raised $500M gross proceeds through Series A, B,IPO andPIPEfinancings to furtherthe development of lorundrostat . Lorundrostatis aselective aldosterone synthase inhibitor that isbeing developedto target masked hyperaldosteronism in cardiorenal metabolic diseases In aphase 2, dose-range findings, proof-ofconceptstudy,lorundrostat delivereddouble-digit placebo-adjusted reduction in systolicblood pressure while demonstrating asafe andwell-tolerated profile .Lorundrostatis currentlyin three pivotalstudiesfor hypertension, PoCfor hypertension andCKD .

SKpharmteco

In October 2023, SK pharmteco acquired a majority stakein the Centerfor BreakthroughMedicines This transformative deal, backed by SK Group’s $22B commitmentto theUS, saw CBMbecomea global powerhouse overnight as part of SK pharmteco’s 2,000 employees, delivering treatments to 70,000 patients annually . Thecollaboration enhances CBM’s advanced therapy capabilities, positioning us as the preeminent Cell andGeneTherapy CDMO in the world .

Sponsor:

Imvaxishonoredtobenominated forLIFESCIENCESAND

andextendsitscongratulationsto theothercategorynominees: AdaptimmuneandBioAnalysis

ImvaxisaPhiladelphia-basedclinical-stagebiotechnology companywithauniqueplatformtechnology,Goldspire™, focusedondeliveringpersonalized,wholetumor-derived immunotherapiesacrossarangeofsolidtumors. www.imvax.com

Qlik

Qlik, withthe recentacquisitionofTalend, T delivers anindustry-leading portfolio ofsolutionsfordataintegration, data quality,and analytics .This includesadvancements in real-time AI, ML,andautomation . Qlik’sacquisition of Talendtiedtogether two data analyticsandvisualizationvendors backed by ThomaBravo,and has allowed customers and partners greateraccessto complementary products supporting the entire lifecycleof dataandanalytic needs . Together,their complementarysolutionsextendthe capabilities of manyvital areas such as data quality,transformation, application connectivity, andAPI services .

Tendo

Tendocreates seamless care experiences, connectingpatients,clinicians, and caregivers with intuitive, intelligent software andanalytics .Weenvision ahealthier, connected world without the frustrationthat resultsfromthe current fragmented healthcare landscape . Weacquired MDsave, the largest US healthcare network, featuring 350+ hospitals and 5000+ care sites, with 15 patents forinnovativebundled andvirtual care With this integration, we now canoffer unparalleled transparency, allowing patients to access, schedule, and engage incare with ease . This acquisitiondrives digital transformation, providing the most comprehensivesolution for patients’ healthcare needs,bridgingthe gap in today’s complexhealthcare ecosystem .

Transcend

TranscendSoftware, the leading SaaSprovider of generative designtools for criticalinfrastructure, announced theclose of a $20M Series Bfinancing round in 2023 .Participantsincluded Autodesk, a leading software provider forthe architecture, engineering, construction, manufacturing, product design, and media industries .Existing investors HG Ventures, PureTe e rraand Aspen Capital Group also participated, along withnew investors ArosaCapital and Riverstone Holdings .Autodesk’s commitment is aclear indicator thatthe world ismoving towards the automation of preliminary designactivities to develop resilient infrastructure for the future

Sponsors:

We salute Karla Trotman on being named a PACT 2024 EnterpriseAward Finalis for Technology CEO

RSMisproudtosupportPACTandthe 2024EnterpriseAwards.

rsmus.com

Adaptimmune

aptimmuneis committedto treating the mostchallenging solidtumors using aproprietary cell therapy platformthatharnesses apatient’s cells to combattheir cancer .We are a fully integratedcompanyonthe verge of anew era .Withourfirst BLAsubmittedto theFDA,we areaiming to commercialize the first engineered T-celltherapy in solid tumors to help improvecancertreatment .

BioAnalysis

BioAnalysis, LLC is asmall,agileCRO . Ourscientistswill collaborate with your team to build productive andeffective solutions The traditional CRO model workswell,butat BioAnalysis, LLCwe believe that collaborative interactions, opencommunication, and robust experimental design are the gold-standardway toproduce valuable results . Oursolutions are carefully designed tosupportyour unique product .With our team of subjectmatter experts, BioAnalysis is focused onproviding the most comprehensiveand scientifically robust analysisavailable Our experience ensures the highest standardsofscientificrigorare appliedto every projectwhile ourthorough investigation ensures completeresults without unnecessary experiments

Imvax

Imvax isaclinical-stagebiotechnology companywith a unique platform technology, Goldspire™, focused on delivering personalized,whole tumorderived immunotherapiesacrossarange of solid tumors . Imvax’s most advanced program, IGV-001, is currently beingevaluated in a Phase2b clinicaltrial innewly diagnosed glioblastoma patients Imvax’s portfolio also includesseveral otherprogramsdesigned to stimulate a patient’s immunesystem against the entireantigen signature of theirtumor . Imvax is headquartered in Philadelphia, Pennsylvania

Sponsor:

DuaneMorrisLLPisalaw firmwithmorethan900attorneysinofficesacrosstheUnitedStates andinternationally.Weworkwithentrepreneursandinvestorsthroughoutallstagesofthebusiness life-cycletoimplementcreativeandpracticalstrategiestoaccomplishtheirbusinessobjectives.

RichardL.Cohen

Co-Chair,EmergingCompanies/VentureCapital

215.979.1233|rlcohen@duanemorris.com

RebeccaA.Guzman

302.657.4928|raguzman@duanemorris.com

MichaelS.Harrington

Co-Chair,EmergingCompanies/VentureCapital

215.979.1260|msharrington@duanemorris.com

ElizabethG.Hodgson

215.979.1262|ehodgson@duanemorris.com

DuaneMorris–FirmandAffiliateOffices|NewYork|London|Singapore|Philadelphia|Chicago|Washington,D.C.|SanFrancisco|SiliconValley SanDiego|LosAngeles|Boston|Houston|Dallas|FortWorth|Austin|Hanoi|HoChiMinhCity|Shanghai|Atlanta|Baltimore|Wilmington Miami|BocaRaton|Pittsburgh|Newark|LasVegas|CherryHill|LakeTahoe|Myanmar|DuaneMorrisLLP–ADelawarelimitedliabilitypartnership

www.duanemorris.com

Broadpathisproudtosupport PACTandthe2024Enterprise Awards.Congratulationstoall ofthefinalistsandhonorees.

Broadpathhelpstechnologycompanies leadtheirindustrydialogue.Weareexperts atcraftingleading-edgecontent,capturing credibleearnedmedia,andoptimizing generativeAIresults.

info@broadpathpr.com Broadpathpr.com

TechnologyEmerging

Burro

Burro,headquartered in Philadelphia, is a robotics company focused on ridding theworld of tedious work outdoorsthrough the use ofcollaborative robots .Burro’s main products, Burro,BurroXL, andBurro Grande, amplify the workforce bycarrying, towing, scouting,andpatrolling .Today, there are over 350Burrosin paid commercial usewith customers, operating on6 continents,having worked over 75,000autonomous miles Burroclosed a $24MSeries BinDecember2023, whichwillbeusedto investin building outitsgotomarket and product teams .

Cesium

Cesium providesan open software platformforcreating 3D geospatial applicationson the web or in popular game engines such as Unreal Engine andUnity . With Cesium’stechnology,developers in industries such as Architecture, Engineering &Construction (AEC),Aerospace &Defense,and Smart Citiesstream massive amounts of real-world data to createvirtual worldsfor visualization, analysis, andsimulation Cesiumhas grown quickly, moving into largeheadquartersin Old City Philadelphia, whichtheyopen up for community events suchas Philly JS Meetups,hackathons, andBlack Tech Philly WeekendWorkshops . Cesiumis enthusiastically dedicatedto building thePhiladelphia tech community

DrayNow

DrayNowis revolutionizingintermodal’s firstand lastmile to create unexpected opportunitiesand exceptional value . Ourgoalis to make intermodal-themost environmentally sustainablemode ofdomestic freight transportation - more efficient, more cost-effective, and ultimately thepredominant mode for moving domestic freight DrayNow’splatform connects small fleet owneroperators with brokers, IMCs, & BCOs who need first andlast mile drayage service Ourtechnologyeliminates paperwork, providesreal-timegeo-tracking &ETAs, andintegrates directlywith TMS software via EDI & API- all while extending their operational capacity on demand toprovide unparalleled transparencyand efficiency .

Sponsors:

DonnaDorozinsky, JustInTimeGCP

Founder&CEO ofJust in TimeGCP,Donna Dorozinskyisa visionary leader andentrepreneurwho has over 30years of experiencein drug development andclinical compliance .Sheis deeply passionateabout thebusiness andhas theability to thinkstrategicallywhile payingattentionto operationaldetails Sheis committedto developing heremployees andestablishing a strong culturethathasbuilt the business to whatit is today Under Donna’s leadership, Just inTime GCP hasbeen namedto the INC5000forthe past 3 years andwas mostrecentlynamed an INC500 BestWorkplaces .

HervéHoppenot, Incyte

Forover30years,Hervé Hoppenot has beenat the helmof scientific innovation, makinga tremendousimpact on the biopharma industrythrough hisunwaveringdedication toadvancingsciencethat may solvechallenges for patientswith critical unmet medical needs Since becoming CEO of Incyte in 2014,Hervé has catapultedIncyte forward, further enhancing the company’sreputation asa scientificpowerhouse Hervé’sleadership has yieldedsignificant advancementsfor patients, as well asrobust business growth forIncyte and expanding operations across North America, Europe andAsia .

JamesLovett, Myonex

In the fiveyears with James Lovett asCEO, Myonex has delivered 35% compound growth in earningsper year and tripledemploymentto220+ . Myonex hasdeveloped three newservices in itsmissionto improve how clinicaltrials are supplied, expanding in theUSand UK, and completing an acquisitionin Germany James believes that astrong people orientation, focus on resultsand accountability,and agenuinecommitment to integrity are mutually re-enforcing ratherthanin conflict Great people wantto win and towork ina company wheretheyfeel good abouttheir contributions to society, andclients support this kindof company with great people .

Sponsors:

Early-Stage Ve Venture ure Fir Firm

Business-to-BusinessSoftware With aFocu F son AI-EnabledFutureofWork

Congratulationsto DrayNow and allo ther Finalists!

www.cozen.com/copilot

TechnologyCEO

SuchitBachalli, Unilog

Unilog is the leaderin connected product content and commerce solutionsfor distributors, manufacturers, and specialty retailers As Unilog’s CEO, Suchit Bachallioverseesthe global sales andsolutionconsulting teams anddrives Unilog’sbusiness and sales strategies acrosstheir productportfolio . He has helped buildanecosystem of customersandpartners whoattestto the high-qualitysolutions Unilog delivers Bachalli’sstrong industry knowledge andforward-thinking leadership hasbeen an integral part of Unilog’s success andwas instrumental to securing significantgrowth capitalin 2021 to help himaccomplish hisvision forthe company .

BrianDainis, Curotec

Curotec is asoftware development firm ledby CEO BrianDainis .Brian’s strategyfor growing the company includes fosteringstrongindustry partnerships, buildingeffectivego-to-market channels, andkeepingthe company’s core offerings focusedand relevant . Aboveall, buildingand nurturing ateam culture where top-tiertechnologists can thrive is acorefocusfor Brian .

KarlaTrotman, ElectroSoft

Karla Trotman is the Gen2 owner of Electro Soft Recognizingthegrowth potential ofher familybusiness,shechangedthe business model . Armed withabackgroundinsupplychain logisticsand e-commerce,she leveraged the businessstrongknowledge andtechnicalfoundation to revitalizean otherwiseflatrevenuestreak, attaining 20%+ year-over-yeargrowth She brought to the forefronttheneed forstrongand knowledgeable manufacturingpartners to bring highlytechnical ideasfrom paper to fruition yet are oftentimes forgotten as they silentlyoperate in the background . Her passion for revitalizingmanufacturing has led to the creationof partnerships and pipelines oftomorrow’smanufacturing leaders .

Sponsor:

WESALUTE

The2024Enterprise Awardwinners

IndependenceBlueCross(IBX)isproudtosupportPACT’s 2024EnterpriseAwards. Werecognizethewinnersfortheirinnovationintechnology,lifesciences,and investmentintheGreaterPhiladelphiaregion.

IBXremainssteadfastinitssupportofindividualsandcommunityorganizations dedicatedtoimprovingthelivesandhealthofthepeopleinourregion.

AscellaHealth

AscellaHealth isa globalhealthcare and specialty pharmacy solutions organization, serving patients, life sciencesmanufacturers, payersand providers .AscellaHealthstands out as a leader in theintricate, competitive specialtypharmaceuticalecosystem,drivenby its unique, patient-centric and collaborative approachthat differentiatesthe Company from other players . AscellaHealth’s uniquely-tailored specialty pharmaceuticalservicesand programs address unmet needsof industrystakeholders andare designedto meet thespecific requirements ofhighlyspecialized patient populations and complex,chronic disease categories . As a healthcare innovator, AscellaHealth leads the industryw r itha patient-centricmodel andtailoredsolutions for optimizing programand patient outcomes .

CabalettaBio

Cabaletta Bio (Nasdaq:CABA) isa clinical-stagebiotechnology company focused on the discovery anddevelopment of novel engineered Tcell therapies thathave thepotential toprovide a deep anddurable, perhaps curative, treatmentforpatients with autoimmune diseases . CABA-201, our investigational CD19-CAR Tcelltherapy, iscurrently advancing in Phase 1/2 clinicaltrialsforlupus, myositis, systemicsclerosisand generalized myastheniagravis, which collectively affect over 500,000 U .S patients We believe CABA-201 may address significant unmet need across a broad range ofautoimmune diseases withthe potential to provide an ‘immunereset,’ enabling patients to achieve durablediseaseremission .

CarismaTherapeutics

Carisma Therapeutics isaclinical stagebiopharmaceuticalcompany developing a differentiatedand proprietary celltherapyplatform focused on engineered macrophagesto transformthe treatment of cancer and other serious illness .

Sponsor:

Affordable,securefinancialreporting softwarefromtheleadingSECfilingagent

VDRs&corporaterepositories optimizedforproductivity

AI-poweredcontractanalytics thatsavetimeandmoney

Proudtosupportinnovatorsandleaders inLifeScienceandTechnology

—

ProudPACTsupportersince2017

AtBoomi,weunderstandthepowerofdataindriving successfuldigitaltransformation.Ourcloud-based integrationplatformsimplifiesconnectivityacross yourentirebusinessecosystem–applications,data, processes,andpeople.It’sdesignedforspeed,easeof-use,andcost-effectiveness.

ThinkofBoomiasyourstrategicintegrationpartner. Wehelpyouunifyyourdataandapplications,creating aseamless flowthatunlocksbetter,fasterresults.

Joinover20,000companieswholeverageBoomias akeydriveroftheirsuccess.LetBoomiempoweryour businesstoachieveitsfullpotential.

www.boomi.com

TributeCompanies